Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report
Date:3/19/2012

RALEIGH, N.C., March 19, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2011, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of the Company's achievements and an update on business operations and upcoming milestones for 2012.

(Logo:  http://photos.prnewswire.com/prnh/20110217/CL49801LOGO

In 2011, BDSI made significant strides in progressing development of its two lead products, BEMA Buprenorphine for chronic pain and BEMA Buprenorphine/Naloxone (BNX) for opioid dependence.  As such, but as expected, BDSI increased its expenditures and therefore reported a net loss of $23.3 million, or ($0.82) per share, for the twelve months ending December 31, 2011, as compared to a net loss of $13.0 million, or $(0.56) per share, for the twelve months ending December 31, 2010.  The increased net loss is due primarily to increased research and development expenses which totaled $20.8 million in 2011, compared to $10.6 million in 2010. Conduct of the Phase 3 trial for BEMA Buprenorphine in chronic pain and initial studies for BNX are primarily responsible for higher research and development expenses in 2011. 

At December 31, 2011, BDSI had $10.8 million in cash compared to $18.2 million at December 31, 2010.  BDSI received an upfront payment of $30 million in early January 2012 with the signing of a license and development agreement with Endo Pharmaceuticals, Inc. (NASDAQ: ENDP) for BEMA Buprenorphine for the treatment of chronic pain.  A $15 million milestone payment, for granting of a patent extending the exclusi
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
7. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
8. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
9. BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
10. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
11. Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... certain mutations enable specific cells in the,retina to ... suggests deliberate,genetic manipulations might coax an injured brain ... Investigators at St.,Jude Children,s Research Hospital have ... cancer retinoblastoma, disproving a long-standing principle of,nerve growth ...
... Oct. 18 CEL-SCI CORPORATION,(Amex: CVM ) ... is a featured presenter at the International Society ... Mr. Kersten will present on the "New Realities ... p.m. (Eastern Daylight,Time). In April 2007, CEL-SCI ...
Cached Medicine Technology:St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 2St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 3CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase 2
(Date:8/29/2014)... San Francisco, CA (PRWEB) August 30, 2014 ... the 10 best web conference providers in the online ... Amongst the list were global leaders Webex, GotoMeeting and ... in the industry users have to determine which provider ... Essentially, web conference businesses search for compelling consumer ...
(Date:8/29/2014)... 2014 Honey Gifts, premium Vancouver adult ... now be selling purse-sized adult toys and erotic products. ... they can be carried in a woman’s purse with ... range at Honey Gifts is also leak-free and will ... rechargeable batteries are common characteristics of Honey Gifts’ portable ...
(Date:8/29/2014)... 29, 2014 Sansego is ... an interactive online community, and a range of personalized ... all the way to professional athletes. Crowie has brought ... been with him throughout the majority of his triathlon ... in the triathlon public. , Sansego provides the following:, ...
(Date:8/29/2014)... Work is the recipient of a ... Drug Abuse (NIDA) at the National Institutes of Health (NIH) ... use. Additionally, the grant provides resources to create the infrastructure ... use has increased steadily since 2007 according to NIDA, as ... and more available opioid. , A primary project at ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Ethane Web ... recently launched a new service named HTML web design. ... based service. Before tailoring the service, Ethane Web Technologies ... other companies. The company has done its best efforts ... and able to deliver outstanding results to clients. ...
Breaking Medicine News(10 mins):Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 3Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Ethane Web Technologies Launches a New Web Design Service 2
... ... DSPanel today announced the availability of their latest ... DSPanel announced the availability of DSPanel Performance Canvas 2.2 with Planning, ... designed to be used as an accompaniment to Sharepoint 2010 and ...
... ... 140-2 Level Certification , ... (PRWEB) May 26, 2010 -- bTrade announced today that the company’s Managed ... Transfer solutions have received the Federal Information Processing Standards (FIPS) 140-2 (Level 1) validation, ...
... ... special section dedicated to prescription sunglasses , ... New Jersey (PRWEB) May 26, 2010 -- With summer quickly ... in selling prescription glasses has been selling prescription sunglasses since ...
... ... take over as President of the company effective July 1st, 2010. , ... Waterloo, IA (Vocus) May 26, 2010 -- John Spragle recently announced ... VGM Insurance,s plan for my successor. Effective June 1, 2010, Tom Jones will be joining VGM ...
... ... and Curcumin have demonstrated anti-tumor properties and may serve as important therapeutic agents in ... anti-cancer chemicals has been the focus of US based Biomedical Company, Millennium Bioceutics with ... ...
... used a magnetic resonance imaging (MRI) technique called continuous ... patterns in schizophrenic patients quickly and without using radiation ... edition and July printed issue of the journal ... technique that can help reduce the cost and complexity ...
Cached Medicine News:Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 2Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 3Health News:bTrade Earns Stringent Government Data Security Certification 2Health News:bTrade Earns Stringent Government Data Security Certification 3Health News:GlassesUSA.com Launches Section for Prescription Sunglasses 2Health News:VGM Insurance President Passes the Baton 2Health News:Natural Chemicals Act As Cancer Killers 2Health News:Blood flows differently through the brains of schizophrenic patients 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The upper body blanket covers the upper torso, arms, neck, and head of the patient....
The Electri-Cool® II is the premier choice when it comes to localized cold therapy systems. system offers the widest variety of application-specific pads and wraps, for your convenience....
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
Medicine Products: